ESMO 2018 Conference Report


The European Society for Medical Oncology meeting has emerged as a premier stage for some of cancer’s biggest breakthroughs, including this weekend’s performance from AstraZeneca and Merck’s Lynparza in ovarian cancer maintenance; last year’s showing for AstraZeneca’s Imfinzi in stage 3 lung cancer; and 2016’s unveiling of results from key lung cancer studies for Merck & Co.’s Keytruda.

For all of the news from this year's conference, get the full report.

This exclusive report is for FiercePharma subscribers only.

GET YOUR COPY
Sign up or Confirm your subscription below